NPC(SH:600713) Shang Hai Zheng Quan Bao·2025-08-15 19:40Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, focusing on low-risk, high-liquidity principal-protected financial products [1] Group 1: Cash Management Implementation - On February 7, 2025, the subsidiary Nanjing Pharmaceutical Kangjie Logistics Co., Ltd. purchased a structured deposit product from Ping An Bank amounting to 142 million yuan, which is 100% principal-protected and linked to exchange rates [2] - The company began redeeming portions of the financial products starting March 19, 2025, recovering 2 million yuan in principal and earning 6,600 yuan in interest, which was returned to the dedicated fundraising account [2] - By April 21, 2025, the company redeemed an additional 3 million yuan, earning 69,808 yuan in interest, and by May 20, 2025, it redeemed 53 million yuan with an interest of 80,000 yuan [3] - As of August 14, 2025, the company redeemed 1 million yuan, earning 2.73 yuan in interest, totaling 61 million yuan redeemed and 149,896 yuan in interest earned to date [4] Group 2: Financial Management Overview - The company has been actively managing its idle raised funds over the past twelve months, focusing on ensuring liquidity and safety in its investments [5]